Syndicate Bio is building the world's richest and most diverse human-health datasets by applying AI/ML to genomic and precision-medicine initiatives across underrepresented regions, principally Africa, to unlock inclusive drug discovery. Abasi Ene-Obong (PhD Cancer Biology, MSc Human Molecular Genetics, KGI) previously co-founded and led 54gene — one of the largest African-genomics biobanks. He's re-attacking the same thesis with a leaner, AI/ML-focused approach alongside Estelle Dogbo and Jumi Popoola. The pattern-match is high — same founder, same thesis, second time — with a corrected structure that avoids the capital-intensity trap that eventually caught 54gene.
Techstars and Gbenga Oyebode (TCVP) validated Abasi's second attempt; StoryHouse wrote $100K at $5M cap in Feb 2024 (Internal). Business developed slowly through 2024-2025 and needed additional capital; in December 2025 StoryHouse made a Pre-Seed Extension via Fund II — $300K in milestone tranches at a $4M cap with a 3x cash-exit lock on both Fund I and Fund II positions, plus a discretionary 20% markdown on the Fund I holding (Internal).
The specific edge — richer African genomic data — is real and unaddressed by every major genomic database. Whether that becomes a revenue-scale business depends on downstream partnerships with pharma buyers of the data, which is the historical failure mode.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Syndicate Bio | AI/ML on richer African human-health datasets for drug discovery | Pre-seed extension Dec 2025 ($4M cap on Fund II tranche) | — |
| 54gene | Abasi's prior African-genomics biobank | Ceased operations | Syndicate is designed to avoid 54gene's capex trap. |
| GenomeAsia | Asian-focused genomic dataset | Consortium | Different region; complementary in the broader "underrepresented genomics" thesis. |
| 23andMe research arm | Broad consumer genomic dataset | Public | Overwhelmingly European ancestry; not a substitute for African-focused data. |
Moat: Abasi's network across African research institutions and Ministry of Health relationships built at 54gene — hard to replicate for a new entrant, and Syndicate has the added benefit of learning what did not work last time.
The Fund II extension's 3x cash-exit lock explicitly caps downside — StoryHouse gets 3x back on cumulative revenue milestones regardless of equity outcome. Upside comes from pharma-partnership traction.
Portfolio touchpoint on revenue trajectory ahead of the Fund II extension conversation.
RAW NOTES: Portfolio touchpoint on revenue trajectory ahead of Fund II extension conversation.
Portfolio check-in during the difficult fundraising stretch.
RAW NOTES: Portfolio check-in during a difficult fundraising stretch.
Detailed conversation on fundraising process, 54gene perceived-risk overhang, grant applications, and Abasi injecting personal capital to extend runway one month.
RAW NOTES: Met with Maddie, Waiz, Jung, Jane, Clay, David. Intros: 8VC (via Clay), MSV (pass), Undeterred (waiting), Civilization (waiting), Deepchecks. Reached out to Maya and Healthcap — Healthcap IC interested, excited to hear about the 54Gene acquisition. He feels one issue with fundraise is level of perceived risk because of 54gene. Also speaking with Hack VC; they want runway visibility. Grants: Thermofisher $270K applied. Antler, YC, Techstars, Mucker considered. Runway: Paid folks this month; Abasi put in $40K himself since $50K didn't come through. Summary: Tough position, needs lead investor quickly.